Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis

摘要: Multiple sclerosis (MS) is the most common disabling neurological disease in young women of childbearing age and has an increasing incidence [1]. Recently Salminen et al. [2] analyzed outcome 14 pregnancies with MS exposed to glatiramer acetate (GA) treatment during pregnancy, which nine conceived under GA continued therapy pregnancy postpartum period. These were patients higher activity; interestingly, only one patient on continuous experienced two relapses The authors concluded that it may be reasonable continue those previous activity pregnancy. did not follow interferon (IFN)-beta pregnancies, widely used immunomodulatory drug MS, mainly due FDA C ranking, because a reduced birth weight observed by Boscovic [3] possible increase abortion rate (largely based animal data). Actually, IFN-beta are advised stopped prior anticipated or at moment when recognized, although IFNs labeled now given after risk–benefit consideration. We present data IFN Out our nationwide database (including 400 pregnancies) we followed seven (mean 30.3 years; mean duration 6.5 years) continuing (IFN mothers) throughout postpartum, three 35.7 9.3 (GA mothers). Whilst none mothers had relapse year before first 6 months showed activity. Four During trimester occurred, second respectively. Birth was lower newborns 3,141.7 g vs. 3,443.6 newborns), but born earlier [gestational week (gw) 38.3 39.7]. However, these differences caused medical problems. In each group malformation occurred; boy whose mother injected 1a gw 40 (4,390 g, 52 cm) valvular stenosis pulmonal artery. other until 36 ? 2 (2,505 49 penile hypospadia, will surgically corrected. All breastfed exclusively children noticeable problems, whilst 1a. Our observational case series IFNbeta exposure whole period IFN-mothers K. Hellwig received speaker honoraria from Merck Serono, Bayer Schering healthcare, Biogen Idec Teva Sanofi-Aventis. R. Gold